Adicet Bio

growth-positive

Adicet Bio, Inc. has completed its merger with resTORbio, Inc. and will begin trading on the Nasdaq Global Market under the ticker symbol ACET. The company focuses on developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet plans to advance its pipeline of gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies, to enhance tumor targeting and improve immune response. The merger transaction resulted in a 7:1 reverse split of resTORbios common stock. Adicet anticipates filing an IND for ADI-001 CD20 gamma delta CAR-T and initiating a Phase 1 clinical study for non-Hodgkins lymphoma. The company also plans to file an IND for ADI-002 GPC3 gamma-delta CAR-T and initiate a Phase 1 clinical study for hepatocellular carcinoma and other solid tumors. The merger was advised by JMP Securities LLC, and the combined company will be led by Chen Schor as President and CEO.

growth-positive

Biopharmaceutical companies resTORbio, Inc. and Adicet Bio, Inc. have announced a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications. Under the terms of the agreement, Adicet would merge with a wholly-owned subsidiary of resTORbio in an all-stock transaction, and the equityholders of Adicet will become the majority owners (75%) of resTORbio’s outstanding common stock upon the close of the merger. The transaction is expected to close in the second half of 2020.

growth-positive

Adicet Bio Inc., a US biopharmaceutical company, has raised $80 million in a Series B financing round. The funding was led by new investors including Marius Nacht and Dr. Yair Schindels aMoon2 Fund, with participation from existing investors. Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells. The financing will allow the company to continue developing their proprietary technology and advance their programs in Non-Hodgkins Lymphoma and solid tumors.

growth-positive

Adicet Bio Inc., a Menlo Park-based allogenic immunotherapy company, has raised an $80 million series B funding round. The funding round was participated by Johnson & Johnson Innovation, aMoon2 Fund, Samsung Venture Investment Corp., and existing investors Orbimed Israel Partners Ltd., Novartis Venture Fund, and Pontifax Ltd. Adicet develops universal immune cell therapies based on gamma delta T cells to treat different forms of cancer. The company plans to use the funding to develop its proprietary technology for the treatment of Non-Hodgkin’s Lymphoma. Adicet has raised a total of $131 million to date and employs a team of 61 people in the U.S. and Israel.